Longitude Capital's 4.1% Stake and Phase 3 Milestone Propel CG Oncology's BLA Countdown

Introduction

CG Oncology, Inc. (Nasdaq: CGON; Korean: CG 온콜로지) is a late-stage clinical biopharmaceutical company headquartered in Irvine, California. Founded in 2010, the company develops oncolytic immunotherapies aimed at bladder-sparing treatment of non-muscle invasive bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is administered intravesically and is currently in a Phase 3 trial (PIVOT-006) for BCG-unresponsive disease, with additional Phase 2 studies in combination with pembrolizumab (KEYTRUDA®) and nivolumab (OPDIVO®).

Corporate Structure

CG Oncology maintains a workforce of approximately 51–200 employees engaged in research, clinical development, and corporate functions. Its executive leadership includes Arthur Kuan, Chairman and Chief Executive Officer, and Ambaw Bellete, President and Chief Operating Officer. The company conducts regular engagements with investors and scientific forums to discuss clinical progress and governance.

Oncolytic Immunotherapy by National Cancer Institute

Recent Developments and News

On September 6, 2025, CG Oncology announced updated safety and efficacy data from its BOND-003 Cohort C study, which was presented by Trinity J. Bivalacqua, MD, PhD, at the American Urological Association’s New England Section meeting in Boston. On September 9, the company filed a Current Report on Form 8-K (Items 7.01 and 9.01), outlining corporate events and operational updates.

A Schedule 13D filed on September 18, 2025, disclosed that Longitude Capital Partners IV, LLC acquired 3,190,463 shares, representing 4.1% of outstanding common stock. The same filing reported that Seven Fleet Partners LP and related entities hold a total of 1,515,151 shares, or 1.9%. On September 11, 2025, the reported purchases by Seven Fleet indicate changing ownership dynamics as the company approaches its Biologics License Application (BLA) submission planned for Q4 2025.

Financial and Strategic Analysis

As of October 28, 2025, CG Oncology’s shares traded at $44.29, with no change for the day. The trading volume was 1,278,867 shares compared to an average daily volume of 105, indicating considerable investor interest surrounding trial milestones and upcoming regulatory filings.

Major shareholders now include Longitude Capital Partners IV, which holds 4.1% of the company, and Seven Fleet Partners LP with 1.9%. This concentration of ownership may influence governance and strategic decisions within the company. With enrollment completed in the PIVOT-006 trial, CG Oncology aims to file its BLA for cretostimogene grenadenorepvec in the fourth quarter of 2025.

Market Position and Industry Context

CG Oncology operates in the urologic oncology segment, where bladder cancer treatments have focused on intravesical BCG and systemic immune checkpoint inhibitors. The company's oncolytic immunotherapy approach is designed to enhance tumor response while preserving bladder function. Key industry players in immuno-oncology include Merck (KEYTRUDA®) and Bristol Myers Squibb (OPDIVO®). Successful Phase 3 results and subsequent regulatory approval could establish CG Oncology as a provider of a bladder-sparing therapy within a market with an estimated annual incidence exceeding 80,000 new cases in the U.S.

tl;dr

On September 18, 2025, Longitude Capital Partners IV reported a 4.1% stake in CG Oncology. The company completed enrollment in its Phase 3 PIVOT-006 trial and presented updated data from the BOND-003 cohort on September 6. With a planned BLA submission in Q4 2025 and a share price of $44.29 (volume 1.28 million), CG Oncology is preparing for a critical regulatory and commercial phase.